STUDY SEARCH RESULTS

1 study found for your search request:  3475-522

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Thera...
Condition: Triple Negative Breast Neoplasms
Minimum Age: 18 years, Maximum Age: N/A
Gender: Both
Study ID: NCT03036488
Status: Completed




Copyright © 2026 · Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved. · This site is intended only for residents of the United States.
Cookie Preferences  Privacy  Terms of Use  Consumer Health Data Privacy Policy  Your Privacy Choices   Accessibility  U.S. Corporate Site